Navigation Links
Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Date:9/4/2009

DEERFIELD, Ill. and OSAKA, Japan, Sept. 4 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl). The FDA informed Takeda on June 26, 2009 that further review of the alogliptin monotherapy NDA would be conditional based upon additional data from a cardiovascular (CV) safety study that satisfies the statistical requirements of the December 2008 FDA Guidance titled, "Guidance for Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes."

"This complete response letter from the FDA is consistent with the June 26 complete response letter for alogliptin, a key component of the alogliptin and ACTOS fixed-dose combination product," said Nancy Joseph-Ridge, M.D., general manager, Pharmaceutical Development Division. "The FDA recently agreed to the study design for a cardiovascular outcomes trial for alogliptin, titled EXAMINE, and patient enrollment is planned to begin this month. We anticipate that the EXAMINE trial will provide the FDA with the information needed to continue the NDA reviews of both the alogliptin monotherapy and the alogliptin and ACTOS fixed-dose combination."

The complete response letter was specific to the FDC of alogliptin and ACTOS, and did not include any new questions or concerns about alogliptin or ACTOS.

About ACTOS(R) (pioglitazone HCl)

ACTOS is a prescription medication used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for patients with type 1 "juvenile" diabetes or diab
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
2. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
3. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
4. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
5. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
6. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
7. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
8. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
9. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
10. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
11. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)..., CHICAGO, Nov. 29 This year at th...entific Assembly and Annual Meeting, FUJIFILM Medi...e advanced visualization space with the introducti...s core strength in image processing by now offerin...eneral radiographic and cardiovascular application...
(Date:11/27/2009)..., SALT LAKE CITY, Nov. 27 /PRNewswire-FirstCall...stems, Inc. (NYSE: VAR ), a premier supplier of ..., will exhibit its full range of detectors at the ... 29 - December 3, 2009. Varian will also be exhib...s as well as specialized cancer treatment technolo...
(Date:11/25/2009)..., CANOGA PARK, Calif., Nov. 25 P...ace rankings in the American Academy of Family Phy...009 EHR User Satisfaction Survey for improving med...gement, all critical for new ARRA Stimulus legisla...ng their EMR had a positive effect in determining ...
Breaking Medicine Technology:FUJIFILM Enters Advanced Visualization Market 2FUJIFILM Enters Advanced Visualization Market 3FUJIFILM Enters Advanced Visualization Market 4Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2URI researcher sheds light on man eating squid 3B finds them timid non threatening 9340 1URI researcher sheds light on man eating squid 3B finds them timid non threatening 9340 2URI researcher sheds light on man eating squid 3B finds them timid non threatening 9340 3Northwest Biotherapeutics Announces Plans to De list From AIM and Consolidate its Stock Market Listing in U S 13177 1Northwest Biotherapeutics Announces Plans to De list From AIM and Consolidate its Stock Market Listing in U S 13177 2Northwest Biotherapeutics Announces Plans to De list From AIM and Consolidate its Stock Market Listing in U S 13177 3Emphysema severity directly linked to coal dust exposure 52621 1Emphysema severity directly linked to coal dust exposure 52621 2Emphysema severity directly linked to coal dust exposure 52621 3
...cin Studies Presented at ECCMID/ICC, MUNICH, Germa...eutics today announced results from two studies sh...bacterial growth in vitro,when tested with a commo...onstrating the activity of oritavancin against S.,...cin, a novel,lipoglycopeptide antibiotic, is Targa...
...ys Show rBChE Suppresses Amyloid Plaque,Formation ...., a leading,biodefense company specializing in th...ntermeasures against chemical and,biological terro...binant butyrylcholinesterase (rBChE) research prog...al Conference on,Alzheimer,s and Parkinson,s Disea...
Other Medicine Technology:Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 2Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 3Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 4Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 5Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics 6Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6
(Date:11/29/2009)... Moravia,s Nanjing-based Service Deliver...ce , Brno, Czech Republic...tion solution provider, is pleased to announce its... 2009, to be held in Nanjing, China, on November 3...Union-based companies that have established and gr...
(Date:11/29/2009)... CA--New connections begin to form between brain c...k, according to a study published this week in Na...ifornia, Santa Cruz, the study involved detailed o...ace in the brain during motor learning. , The re...ch through a slot to get a seed. They observed rap...
(Date:11/29/2009)...aware the sleep disorder boosts urine production, ...Day News) -- People who wake up during the night t...al problem. Sleep apnea, a breathing-related sleep...ggests that nighttime urination, or nocturia, is c...ive sleep apnea, a disorder in which soft tissue i...
(Date:11/28/2009)...HICAGO, Nov. 28 Get ready for a... the clinical routine when Siemens introduces ...ly and Annual Meeting of the Radiological Society ...er 3 at McCormick Place (Booth #825, East Building...o. via , Siemens, new imaging software for mu...
(Date:11/27/2009)...DFORD, Mass., Nov. 27 GS...a supplier of precision technology products and se...l meeting of the Company,s shareholders has been s... location of the meeting will be announced in due ...ived a requisition notice from Stephen Bershad, a ...
Breaking Medicine News(10 mins):Health News:Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China 2Health News:Study shows new brain connections form rapidly during motor learning 2Health News:Study shows new brain connections form rapidly during motor learning 3Health News:Sleep Apnea May Cause Nighttime Urination 2Health News:Sleep Apnea May Cause Nighttime Urination 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:GSI Group Calls Shareholders Meeting 2
...e sex hormone testosterone, which plays a key role...mer's, a progressive brain disorder.// People...arn, make judgments, communicate and carry out dai...ation, as well as delusions or hallucinations. ...
...nologies (LCT) Limited has published evidence outl...rcine islet cells and insulin production in a huma...l transplant. The scientific paper publishe...ion of its encapsulated porcine islets in a human ...
...a-burning women libbers would love to endorse. // ...s, revised edition 2001) by authors Sydney Ross Si...) had come out with claims that wearing a bra thr... interviews of 4,730 women in five major US cities...
...d in their obsession for that ‘bronzed and beautif... trend, opine researchers. // According to a r...Journal of Public Health, the increases in people ...en sunbed use and increased risks of melanoma, as ...
... reduce the number of infants and toddlers develop...y. //The research was carried out by Katherine A. ...’s Hospital, part of Wake Forest University Baptis... and a team of researchers followed about 27,000 c...
... by NHS dentists last year, has left Health Trusts...ral Democrats.// The figures from a local s...ters of Primary Care Trusts have received much les...ervices provided by it, such as sexual health and ...
Other Medicine News:Health News:Transplanted Pig Cells in Human Produce Insulin 2Health News:Transplanted Pig Cells in Human Produce Insulin 3Health News:Breast Cancer and Bra Wearing: Possibly Linked 2Health News:Sultans of Suntans Warned 2Health News:Vaccine Helps Reduce Frequent Ear Infections 2
FilteredFlo® Air Warming Blankets
MAMMOMAT 3000 Nova Mammography System
ActiveLife® One-Piece Cut-to-Fit Urostomy Pouch With Stomahesive® Skin Barrier
Contour I Drainable Pouch, Oval Cut-to-Fit Skin Barrier
Medicine Products: